Ignite Creation Date:
2024-05-06 @ 8:20 AM
Last Modification Date:
2024-10-26 @ 11:59 AM
Study NCT ID:
NCT02717962
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-11-22
First Post:
2016-03-16
Brief Title:
Study of VAL-083 in Patients With MGMT Unmethylated Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
Sponsor:
Kintara Therapeutics Inc
Organization:
Kintara Therapeutics Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Brain Cancer |
| Glioma |
| Glioblastoma |
| Glioblastoma Multiforme |
| GBM |
Keywords:
| Name | View |
|---|---|
| adjuvant therapy | View |
| Glioma | View |
| Glioblastoma | View |
| Glioblastoma multiforme | View |
| GBM | View |
| brain tumor | View |
| brain cancer | View |
| recurrent brain tumor | View |
| recurrent brain cancer | View |
| refractory brain tumor | View |
| refractory brain cancer | View |
| recurrent GBM | View |
| refractory GBM | View |
| recurrent glioma | View |
| refractory glioma | View |
| recurrent glioblastoma | View |
| refractory glioblastoma | View |
| recurrent glioblastoma multiforme | View |
| refractory glioblastoma multiforme | View |
| failed bevacizumab | View |
| temodar failure | View |
| temozolomide failure | View |